Clinical bottom line
Anti-CD22 monoclonal antibody therapies represent an emerging class of targeted treatments primarily used in relapsed or refractory B-cell malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). These agents, including antibody-drug conjugates and CAR T-cell products, have demonstrated promising efficacy but also carry risks of infection due to B-cell depletion and immunomodulation. Current evidence suggests that patients receiving anti-CD22 therapies are at increased risk for serious infections, including bacterial, viral, and opportunistic pathogens, warranting vigilant infectious disease monitoring and prophylactic strategies tailored to this population. However, data on infection risk profiles and optimal management remain limited and largely extrapolated from experience with other B-cell–targeted therapies.
What the evidence shows
Anti-CD22 monoclonal antibodies target CD22, a B-cell surface antigen involved in cell signaling and survival, enabling selective depletion of malignant B cells (Hoelzer et al., 2013). Early-phase clinical trials of anti-CD22 antibody-drug conjugates such as DCDT2980S have demonstrated antitumor activity in relapsed/refractory B-cell malignancies with manageable toxicity profiles (National Cancer Institute et al., 2020). Pharmacokinetic and tolerability studies in patients with CD22-positive NHL confirm acceptable safety but highlight immunosuppressive effects (Li et al., 2012).
Infectious complications associated with anti-CD22 therapies have been reported but are less well characterized than those seen with anti-CD20 or anti-CD38 antibodies. The Emerging Infections Network study on biologic therapies including anti-TNF agents underscores the potential for serious infections with novel immunomodulators, suggesting a need for heightened vigilance in patients receiving new monoclonal antibodies (Winthrop et al., 2008). Although this study did not specifically address anti-CD22 agents, the immunosuppressive mechanism via B-cell depletion is shared, implying a similar infection risk.
CAR T-cell therapies derived from anti-CD22 antibodies have shown efficacy in blood cancers but also carry infection risks related to profound and prolonged B-cell aplasia and cytokine release syndrome (Ruengdej et al., 2025). Experience from anti-CD38 monoclonal antibodies, which also target hematologic malignancies, provides practical insights into infection prevention and management strategies applicable to anti-CD22 therapy recipients (Moreau et al., 2015).
Preclinical work with the HB22.7 anti-CD22 monoclonal antibody platform demonstrates potent cytotoxicity against lymphoma and ALL cells, supporting ongoing clinical development (Boyle et al., 2012). However, infection risk data remain sparse, highlighting a critical knowledge gap.
Caveats and uncertainty
The evidence base for infection management in patients receiving anti-CD22 monoclonal antibodies is limited by small sample sizes, heterogeneous patient populations, and short follow-up durations in clinical trials. Most infection risk data are extrapolated from studies of other B-cell–targeted therapies or broader biologic agents, which may not fully capture the unique immunologic effects of anti-CD22 agents.
No large-scale prospective studies have systematically characterized the incidence, spectrum, or timing of infections in this population. The impact of combination regimens, prior therapies, and patient comorbidities on infection risk remains unclear. Additionally, optimal prophylactic antimicrobial strategies, vaccination timing, and monitoring protocols have not been established specifically for anti-CD22 therapies.
Given the novelty of these agents and evolving clinical use, real-world evidence and postmarketing surveillance will be essential to refine infection risk assessment and management guidelines.
How this may change practice
Clinicians managing patients receiving anti-CD22 monoclonal antibody therapies should maintain a high index of suspicion for infectious complications, particularly in the context of B-cell depletion and immunosuppression. Baseline infectious risk assessment, including screening for latent infections, should be considered prior to therapy initiation.
Prophylactic measures may include antimicrobial agents targeting common bacterial and viral pathogens, although specific recommendations await further evidence. Vaccination strategies should be optimized before therapy when feasible, recognizing potential impaired vaccine responses during treatment.
Close clinical monitoring for signs of infection, early diagnostic evaluation, and prompt treatment initiation are critical. Multidisciplinary collaboration between oncology and infectious disease specialists is advised to tailor infection prevention and management plans.
Ongoing research and clinical experience will inform evidence-based guidelines, but current practice should err on the side of caution given the potential for serious infections in this vulnerable population.